

Personal Information

Web: <http://aves.istanbul.edu.tr/70/>

International Researcher IDs

ORCID: 0000-0003-4636-2595

Publons / Web Of Science ResearcherID: HKF-3015-2023

ScopusID: 57205608177

Yoksis Researcher ID: 165583

Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases**
Kahraman S., Karakaya S., Kaplan M. A., SEZGİN GÖKSU S., Ozturk A., Isleyen Z. S., HAMDARD J., Yildirim S., Dogan T., Isik S., et al.
Scientific Reports, vol.14, no.1, 2024 (SCI-Expanded)
- II. **Does the Timing of Cytoreductive Nephrectomy Impact Outcomes? Analysis of REMARCC Registry Data for Patients Receiving Tyrosine Kinase Inhibitor Versus Immune Checkpoint Inhibitor Therapy**
Meagher M. F., Minervini A., Mir M. C., Cerrato C., Rebez G., Autorino R., Hampton L., Campi R., Kriegmair M., Linares E., et al.
European Urology Open Science, vol.63, pp.71-80, 2024 (SCI-Expanded)
- III. **Therapeutic efficacy of high-dose chemotherapy with autologous stem-cell transplantation in 44 relapsed or refractory germ-cell tumor patients: A retrospective cohort study**
Ferhatoglu F., Paksoy N., Khanmammadov N., YILDIZ A., AHMED M. A., Gülbas Z., BAŞARAN M.
Medicine, vol.103, no.8, 2024 (SCI-Expanded)
- IV. **The effect of parity, breastfeeding history, and duration on clinical and pathological characteristics of breast cancer patients**
Ak N., Tuz Z., Aydin E., Ferhatoglu F., SARI M., Paksoy N., Doğan I., Yildiz A., Dişçi R., Saip P. M.
Turkish Journal of Medical Sciences, vol.54, no.1, pp.229-238, 2024 (SCI-Expanded)
- V. **Single-agent temozolomide as salvage therapy in heavily pretreated metastatic sarcoma patients**
Dogan I., Paksoy N., BAŞARAN M.
Journal of Cancer Research and Therapeutics, vol.20, no.1, pp.93-97, 2024 (SCI-Expanded)
- VI. **Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression**
DOĞAN İ., Aydin E., KHANMAMMADOV N., Paksoy N., Saip P., AYDINER A.
Scientific Reports, vol.13, no.1, 2023 (SCI-Expanded)
- VII. **Long-term outcomes and predictors of recurrence in node-negative early stage breast cancer patients**
DOĞAN İ., Aydin E., KHANMAMMADOV N., Paksoy N., Ferhatoglu F., AK N., Emiroglu S., İBİŞ K., Onder S., Tukenmez M., et al.
Journal of Cancer Research and Clinical Oncology, vol.149, no.16, pp.14833-14841, 2023 (SCI-Expanded)
- VIII. **Comparison of second-line treatments in metastatic renal cell carcinoma patients: A single-center experience**
Pehlivan M., Paksoy N., Aydin E., BAŞARAN M., EKENEL M.
Medicine, vol.102, no.41, 2023 (SCI-Expanded)

- IX. **Efficacy and outcomes of systemic chemotherapy in posttransplant and immunosuppression associated Kaposi sarcoma: Twenty years experience of a tertiary cancer center**
Khanmammadov N. A., Paksoy N., DOĞAN İ., Ferhatoğlu F., Saip P., Aydinler A.
Medicine, vol.102, no.39, 2023 (SCI-Expanded)
- X. **Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer**
Kahraman S., Erul E., Seyyar M., GÜMÜŞAY Ö., Bayram E., Demirel B. C., Acar O., AKSOY S., Baytemur N. K., ŞAHİN E., et al.
Future oncology (London, England), vol.19, no.10, pp.727-736, 2023 (SCI-Expanded)
- XI. **Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy**
Karacin C., Oksuzoglu B., Demirci A., KESKİNKILIÇ M., Baytemür N. K., Yılmaz F., Selvi O., Erdem D., Avşar E., Paksoy N., et al.
BMC cancer, vol.23, no.1, pp.136, 2023 (SCI-Expanded)
- XII. **Fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) regimen in the first-line treatment of metastatic gastric cancer: A single-center experience**
TAŞTEKİN D., Paksoy N., DOĞAN İ., Ferhatoglu F., KHANMAMMADOV N., Bozbey H. U., KARABULUT S.
Journal of cancer research and therapeutics, vol.19, no.2, pp.253-258, 2023 (SCI-Expanded)
- XIII. **Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group**
GÜRBÜZ M., Kilickap S., BİLİCİ A., Karadurmus N., Sezer A., ŞENDUR M. A. N., PAYDAŞ S., ARTAÇ M., Fulden Yumuk P., GÜRSOY P., et al.
MEDICINE, vol.101, no.50, 2022 (SCI-Expanded)
- XIV. **High-dose chemotherapy followed by autologous stem cell transplantation for adult patients with first relapse of Ewing's sarcoma: A single institution experience**
PAKSOY N., FERHATOĞLU F., DOĞAN İ., KHANMAMMADOV N., Iribas Celik A., Gulbas Z., BAŞARAN M.
Medicine (United States), vol.101, no.49, 2022 (SCI-Expanded)
- XV. **Toxicity management and efficacy of carboplatin desensitization therapy for recurrent epithelial ovarian carcinoma: A real-world study**
PAKSOY N., KHANMAMMADOV N., DOĞAN İ., FERHATOĞLU F., YILDIZ A., AK N., AYDINER A.
Medicine (United States), vol.101, no.45, 2022 (SCI-Expanded)

Articles Published in Other Journals

- I. **Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study**
FERHATOĞLU F., ÇAĞATAY T., OKUMUŞ G., AYDINER A., PAKSOY N., VATANSEVER S., AYDIN E., SAİP P.
Eurasian Journal of Medical Investigation, vol.7, no.2, pp.101-106, 2023 (Peer-Reviewed Journal)
- II. **Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors**
DOĞAN İ., KHANMAMMADOV N., PAKSOY N., VATANSEVER S., SAİP P., AYDINER A.
Eurasian Journal of Pulmonology, vol.25, no.1, pp.27-32, 2023 (Peer-Reviewed Journal)
- III. **Prognostic Factors Influencing Progression-Free Survival in HER2-Positive Metastatic Breast Cancer Patients Who Were Treated with A Combination of Lapatinib and Capecitabine**
DOĞAN İ., Paksoy N., AK N., VATANSEVER S., Saip P., AYDINER A.
European Journal of Breast Health, vol.19, no.2, pp.128-133, 2023 (Scopus)
- IV. **Weekly paclitaxel treatment in the first-line therapy of classic Kaposi sarcoma: A real-life study**
Paksoy N., KHANMAMMADOV N., DOĞAN İ., Ferhatoğlu F., AHMED M. A., Karaman S., AYDINER A.
Medicine (Spain), vol.102, no.5, 2023 (Scopus)
- V. **Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study**
Paksoy N., Ferhatoglu F., DOĞAN İ., Khanmammadov N., Bozbey H. U., KARABULUT S., Tastekin D.

Refereed Congress / Symposium Publications in Proceedings

- I. **Safety and survival in adult women with platinum sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program-LynTurk study**
Esin E., Ahmed M. A., Yildirim H. C., Mandel N. M., Erdemoglu E., SARI M., Aydiner A., Arik Z., Gumus M., BAŞARAN M., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 2 - 06 June 2023

Metrics

Publication: 21

Citation (Scopus): 4

H-Index (Scopus): 1